The global Acrocallosal Therapeutics Market is currently valued at USD 147.9 Million in 2023 and is anticipated to expand at a CAGR of 10.8%. Owing to the technological advances in healthcare the market is likely to propel to USD 412.4 Million by 2033.
An increase in the number of patients seeking treatment and rising demand for improved healthcare infrastructure and promising pipeline drugs, and new product launches are likely to drive the growth of the acrocallosal syndrome therapeutics Market in the forecast period.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 147.9 Million |
| Projected Forecast Value (2033) | USD 412.4 Million |
| Global Growth Rate (2023 to 2033) | 10.8% CAGR |
Acrocallosal syndrome is a rare condition also called agenesis of the corpus callosum. Agenesis of the corpus callosum occurs when the tissue that connects the left and right halves of the brain (the corpus callosum) fails to form normally during the early stages of development before birth.
Other brain abnormalities, including the growth of large cysts in brain tissue, have also been reported in people with acrocallosal syndrome. The changes in brain structure associated with this condition lead to delayed development and intellectual disability, which is most often moderate to severe. Some affected individuals also experience seizures.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for acrocallosal syndrome reflected a value of 10.5% during the historical period, 2018 to 2022. Various factors such as awareness of wellness and health and rising healthcare spending across the world are projected to drive the market growth.
The pandemic has also caused supply chain disruptions, impacting the world market for medical products. The pandemic has negatively impacted global financial expectations, supply chains, operations, and crisis response strategies. Due to lockdowns and travel restrictions brought on by the spread of COVID-19, providers of acrocallosal syndrome therapeutics experienced problems.
Other factors such increasing prevalence of genetic disorders, rising awareness about acrocallosal syndrome therapy, technological advancement, and a high rate of Research and Development initiatives are some of the major factors that are driving the acrocallosal syndrome therapeutics market.
Agenesis of the corpus callosum (ACC) is the most common congenital defect of the brain. It is a rare disorder, affecting only 0.05 to 0.07% of the population.
Growing Healthcare Spending to Drive the Acrocallosal Syndrome Therapeutics Market
One of the key driving factors for the growth of the global market has been the increasing activities of research and development to find cures for such rare disorders.
In recent years, there has been a growing prevalence of rare neurological diseases across the globe. Most of them go unnoticed or are underdiagnosed. A lack of effective treatment is the most prominent driving factor for the key players in the market that will help it grow in the coming years of the forecast period.
Another important factor for the growth of the market is the growing focus on fast-track approvals for new and upcoming therapies to treat such disorders. Furthermore, recent technological advancements in the field of neurology and neurobiology have also fueled the development of the global acrocallosal syndrome therapeutics market.
Also, increasing awareness about early diagnosis of these disorders might help the market grow in the coming years.
Principal Consultant
Inadequate reimbursement policies may hamper global market growth.
The high cost involved in treatment, and the increase in complexity of the disease are restraining the acrocallosal syndrome therapeutics market. In addition, patent expiries from many companies and the introduction of generic drugs are expected to restrain the growth of the acrocallosal syndrome therapeutics market.
Expensive diagnosis and inadequate reimbursement procedures are amongst the few factors hindering market growth. However, advantages associated with genetic disease diagnostics are expected to curb the impact of the aforementioned factors.
Also, the lack of medical infrastructure and lack of awareness in certain regions of the world are some of the hurdles that are expected to restrict the growth of this market.
Advancement in Healthcare to Boost the Market Growth in Region
The market in the North American region is anticipated to observe vibrant growth during the forecast period 2023 to 2033. This can be attributed to the growing developments in the healthcare sector as a result of rising research and development activities in this industry. The region is expected to hold the highest CAGR of 10.2% during the forecast period.
North America accounted for the majority of the global acrocallosal syndrome therapeutics market which is closely followed by Europe. Key factors attributing to its large share include the presence of developed healthcare infrastructure in the region, availability of skilled professionals & sophisticated genetic testing equipment, high healthcare expenditure, and better reimbursement policies.
Rising Investments in Research and Development Driving Growth in Europe Market
The acrocallosal syndrome therapeutics market in Europe is predicted to witness substantial expansion during the forecast period, 2023 to 2033. Europe is expected to have the second-largest market for the global acrocallosal syndrome therapeutics market. Increasing awareness among the people about diseases is also a major factor that may boost the growth of the market in this region
The growth of the market can majorly be attributed to the growing need for advanced healthcare services amongst individuals in the region, backed by the rising population across several countries, such as the United Kingdom, France, Germany, Sweden, Netherlands, Italy, and Russia. The European acrocallosal syndrome therapeutics market is expected to rise at a CAGR of 9.5% from 2023 to 2033.
| Attribute | Details |
|---|---|
| United Kingdom | 9.5% |
| India | 9.1% |
| South Korea | 9.7% |
| China | 10.1% |
| USA | 10.2% |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Losmapimod Drug Segment remains dominant among other types
Based on drug type acrocallosal syndrome therapeutics market is segmented into Losmapimod, Praluent, and Evolocumab. Among these, the losmapimod drug segment dominated the market in 2023 with a revenue share of 34.5%.
Losmapimod selectively inhibits enzymes p38α/β mitogen-activated protein kinases (MAPKs), which are modulators of DUX4 expression and mediators of inflammation. Losmapimos is specifically used for the treatment of facioscapulohumeral muscular dystrophy (FSHD).
Injectable Segment to Generate Significantly High Revenue
Based on the route of administration the market is segmented into oral and injectable. The injectable segment accounts for a market share of 36.4% during the forecast period.
Ongoing research and development activities in the field of rare neurological disease treatment are proliferating on the back of increasing demand for orphan drugs. The promulgation of disposable injectors is rapidly covering all aspects of the rare neurological disease treatment market. Hence, the injectable drug is acquiring a leading position.
Furthermore, increasing demand for patient-friendly parenteral drug delivery systems and an increasing number of surgical treatments are expected to boost the growth of the injectable segment over the forecast period.
How do New Entrants Contribute to the Acrocallosal Syndrome Therapeutics Market?
With technological innovations happening at a rapid pace, and companies looking for ways to increase customer engagement, start-ups are taking all possible steps to establish a name for themselves in the acrocallosal syndrome therapeutics market.
Some of the start-ups in the acrocallosal syndrome therapeutics market include-
Arena Pharmaceuticals, Artery Therapeutics, Athera Biotechnologies, Bayer AG, Cardiome Pharma Corp., Cerenis Therapeutics Holding SA, Esperion Therapeutics, GlaxoSmithKline Plc, Lee’s Pharma Corp., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Vitae Pharmaceuticals, Inc. are some of the key players in the acrocallosal syndrome therapeutics industry.
The manufacturers are involved in the production of acrocallosal syndrome therapeutics in a larger capacity. Research and innovation are also conducted to launch innovative products for acrocallosal syndrome therapeutics.
Also, some of the key players are acquiring small pharmaceutical companies to increase their production capacity. Suppliers are focusing on expanding their market presence across the world by initiating new product launches and boosting sales.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of from 2023 to 2033 |
| Expected Market Value (2023) | USD 147.9 Million |
| Projected Forecast Value (2033) | USD 412.4 Million |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million & CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends & Pricing Analysis |
| Segments Covered | Drug Type, Syndromes, Route of Administration, Regions |
| Regions Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East & Africa (MEA) |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, India, Malaysia, Singapore, Thailand, Australia, New Zealand, China, Japan, South Korea, GCC Countries, South Africa, Israel |
| Key Companies Profiled | Arena Pharmaceuticals; Artery Therapeutics; Athera Biotechnologies; Bayer AG; Cardiome Pharma Corp.; Cerenis Therapeutics Holding SA; Esperion Therapeutics; GlaxoSmithKline Plc; Lee’s Pharma Corp.; Pfizer Inc.; Teva Pharmaceutical Industries Ltd.; Vitae Pharmaceuticals, Inc. |
| Customization | Available Upon Request |
The market will generate revenue of USD 147.9 million in 2023.
In 2033, the market is going to generate USD 412.4 million in sales.
The acrocallosal syndrome therapeutics market is forecast to register a CAGR of 10.8% through 2033.
From 2018 to 2022, the global acrocallosal syndrome therapeutics market exhibited 10.5% CAGR.
The rising efforts for research and development to identify remedies have been the primary driving factors for market expansion.
Explore Healthcare Insights
View Reports
Acrocallosal Syndrome Therapeutics Market
